A Prospective Open-label Dose Escalation Phase 1 Study to Investigate the Safety and Tolerability, and to Determine the Maximum Tolerated Dose and Recommended Phase 2 Dose, of HLX10 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 16 May 2019
Price : $35 *
At a glance
- Drugs HLX-10 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Henlix Biotech
- 10 May 2019 Planned End Date changed from 1 Jan 2020 to 31 Aug 2020.
- 10 May 2019 Planned primary completion date changed from 1 Jul 2019 to 30 Jun 2020.
- 26 Mar 2018 New trial record